Fast Five Quiz: Advanced and Metastatic Breast Cancer Myths

Pavani Chalasani, MD, MPH; Stefania Morganti, MD


April 20, 2023

Management guidelines for hereditary breast cancer from the American Society of Clinical Oncology, the American Society for Radiation Oncology, and the Society of Surgical Oncology recommend that germline BRCA1/2 mutation carriers with metastatic HER2-negative breast cancer be offered olaparib or talazoparib as an alternative to chemotherapy. Olaparib and talazoparib have been approved by the US Food and Drug Administration and the European Medicines Agency for deleterious or suspected deleterious germline BRCA-mutated, HER2-negative breast cancer, on the basis of positive outcomes in phase 3 trials (OlympiAD and EMBRACA). Likewise, the NCCN guidelines list olaparib and talazoparib as preferred category 1 agents for treatment of patients with metastatic breast cancer associated with germline BRCA1 and BRCA2 mutations.

Many, but not all, cases of advanced BRCA-mutated breast cancer are triple-negative. Some breast tumors that harbor BRCA mutations, particularly BRCA2, are hormone-positive and may be initially treated with endocrine therapy.

Learn more about use of PARP inhibitors for treatment of advanced BRCA-associated breast cancer.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.